Long-Term IOP Lowering With Bimatoprost in Open-Angle Glaucoma Patients Poorly Responsive to Latanoprost

Sonty, Sriram; Donthamsetti, Vikrant; Vangipuram, Gautam; Ahmad, Ashfaq

doi:10.1089/jop.2008.0033

Cited by 13 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Kammer and colleagues found an additional 1.9 mmHg and 2.1 mmHg mean diurnal IOP reduction from latanoprost mono-treated baseline in glaucoma or OHT patients after 1 and 3 months of bimatoprost 0.03% monotherapy replacement, respectively, and this IOP-lowering efficacy was significantly stronger when compared with switching to travoprost monotherapy [14]. Data from a 24-month study of OAG patients also demonstrated a 15.0–24.0% additional reduction in IOP after changing latanoprost to bimatoprost as monotherapy or in multi-therapy, before adding a further adjunctive agent [30]. Together these results suggest that bimatoprost may provide better IOP control than PGs, which may be attributed in part to its ocular distribution to outflow tissues and dual outflow mechanism following topical administration [9,31].…”

Section: Discussionmentioning

confidence: 99%

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Wang

Yuan

et al. 2014

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundTo report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.MethodsTwo hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.ResultsAmong 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 ± 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 ± 2.8 mmHg (9.5%) to 6.4 ± 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.ConclusionsOur results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Wang

Yuan

et al. 2014

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Prescreening the monkeys for strong responsiveness to PGF 2α -ie may have eliminated some variability in IOP efficacies as reported in humans where nonresponders to latanoprost may still respond to bimatoprost. ((17-19))…”

Section: Discussionmentioning

confidence: 99%

Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in Monkeys

Gabelt

Hennes

Bendel

et al. 2009

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

The aim of this study was to determine whether the magnitude of the intraocular pressure (IOP) lowering response in monkeys to the non-selective prostaglandin (PG)F2a-isopropyl ester (ie) can be reproduced by combining other PG subtype-selective compounds. IOP was lowered by approximately 25% after four to five days of topical administration with latanoprost (FP agonist, 1.5μg, q.d.), bimatoprost (prostamide, whose metabolites have been shown to be FP agonists; 9μg, q.d.), or travoprost (FP agonist, 1.2μg, q.d) or the EP2 agonist butaprost (25μg, b.i.d.). The EP1 agonist, 17-phenyl trinor(PhT)PGE2 b.i.d. and EP3 agonist, sulprostone b.i.d. had no IOP lowering effects. The addition of butaprost, sulprostone (10μg), or 17PhTPGE2 (25μg) to latanoprost did not lower IOP more than latanoprost alone. However, treatment with the combination of latanoprost, 17PhTPGE2, butaprost, and sulprostone produced a similar 50-55% reduction in IOP as did PGF2α-ie (b.i.d.). In conclusion, latanoprost, travoprost and bimatoprost produce similar IOP-lowering responses in normotensive monkeys and are most efficacious when administered q.d. pm compared to b.i.d. The combination of the FP, EP1, EP2, and EP3 agonists used in this study was sufficient to lower IOP by the same magnitude as PGF2α-ie suggesting combining PG-subtype agonists may be a potent anti-glaucoma strategy.

show abstract

“…14,23 Mean IOP before the switch to bimatoprost, however, was approximately 23 mm Hg in their study. 14,23 Our study suggests that the decrease of IOP also occurred with switching to bimatoprost in Japanese patients who are insufficient responders to latanoprost even though pretreatment IOP is low.…”

Section: Discussionmentioning

confidence: 71%

Efficacy and Safety of Switching from Topical Latanoprost to Bimatoprost in Patients with Normal-Tension Glaucoma

Sato

Hirooka

Baba

et al. 2011

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

Long-Term IOP Lowering With Bimatoprost in Open-Angle Glaucoma Patients Poorly Responsive to Latanoprost

Abstract: Significant additional long-term IOP lowering may be achieved by switching to bimatoprost in patients with open-angle glaucoma who are not at target IOP with latanoprost.

Cited by 13 publications

References 14 publications

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in Monkeys

Efficacy and Safety of Switching from Topical Latanoprost to Bimatoprost in Patients with Normal-Tension Glaucoma

Contact Info

Product

Resources

About